Datasets:

nickmuchi

/

trade-the-event-finance

like 7

BEIJING, May 20, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today declared that Xinjiang Deyuan Bioengineering Co., Ltd. ("Xinjiang Deyuan"), China Biologic's source plasma supplier and cooperation partner, has materially breached its strategic cooperation with China Biologic by entering into plasma supply arrangements with Southern Shuanglin Bio-Pharmacy Co., Ltd. ("Shuanglin"), and that China Biologic will take all necessary measures to protect its rights. The Company has learned from a public announcement issued on May 15, 2020 by Shuanglin, a company listed on the Shenzhen Stock Exchange, that Shuanglin and Xinjiang Deyuan have entered into a cooperation framework agreement regarding expansion of plasma collection stations, pursuant to which Xinjiang Deyuan has entrusted five plasma collection stations to Shuanglin and has begun to supply source plasma to Shuanglin after receiving approval from the Xinjiang Heath Commission for the entrustment arrangement, and Shuanglin has paid an initial deposit of RMB40 million to Xinjiang Deyuan (the "Shuanglin Transaction"). The five plasma collection stations that Xinjiang Deyuan entrusted to Shuanglin are among the six stations that Xinjiang Deyuan entrusted to China Biologic under the strategic cooperation agreement (the "Cooperation Agreement") entered into in August 2015 among the Company's subsidiary Guizhou Taibang Biological Products Co., Ltd. ("Guizhou Taibang"), Xinjiang Deyuan and its controlling shareholder (as supplemented by a supplementary agreement entered into in August 2018). Under the Cooperation Agreement, Xinjiang Deyuan has the obligation to supply to Guizhou Taibang no less than 500 tonnes of source plasma over a three year period from August 2018 to August 2021 and as of the date hereof, Xinjiang Deyuan has not fully discharged its plasma supply obligations, with approximately 192 tonnes of source plasma remaining to be supplied to Guizhou Taibang. The entry into the Shuanglin Transaction by Xinjiang Deyuan during the term of the Cooperation Agreement makes the five plasma collection stations entrusted to Shuanglin no longer able to supply source plasma to Guizhou Taibang, which the Company believes constitutes a material violation of the Cooperation Agreement. As previously disclosed in the annual report on Form 20-F filed by the Company with the Securities and Exchange Commission on March 12, 2020, since November 2019, Xinjiang Deyuan has significantly reduced the plasma volume delivered to the Company due to Xinjiang Deyuan's operating cash shortfall and its disagreement with the Company regarding payment arrangements for the plasma, and China Biologic has been negotiating with Xinjiang Deyuan to try to resolve the disagreement. In addition, as part of the Cooperation Agreement, Guizhou Taibang lent to Xinjiang Deyuan a loan with a principal amount of RMB300 million, and as of the date hereof, the outstanding principal amount of the loan is approximately RMB248 million and the overdue interest amounts to approximately RMB10 million. On March 17, 2020, Guizhou Taibang filed two lawsuits against Xinjiang Deyuan in the Beijing Third Intermediate People's Court and the Beijing Chaoyang People's Court, respectively, to demand the repayment of such loan, among other claims. According to Shuanglin's public announcement, Shuanglin was aware of Xinjiang Deyuan's ongoing dispute with China Biologic when entering into the Shuanglin Transaction with Xinjiang Deyuan. China Biologic had no knowledge of the Shuanglin Transaction prior to its public announcement by Shuanglin, and Xinjiang Deyuan did not obtain China Biologic's consent before entering into such transaction. China Biologic views the Shuanglin Transaction as a serious breach of the Cooperation Agreement by Xinjiang Deyuan. The Company will take all necessary measures, including legal actions, to protect its rights and recoup all potential losses due to Xinjiang Deyuan's breach of the Cooperation Agreement, including but not limited to any revenue loss due to Xinjiang Deyuan's failure to supply sufficient source plasma to the Company. The Company will also continue to vigorously litigate the two lawsuits filed against Xinjiang Deyuan. About China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co., Ltd. and its wholly owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. Since the acquisition of TianXinFu (Beijing) Medical Appliance Co., Ltd. in 2018, China Biologic is also engaged in the sale of medical devices, primarily regenerative medical biomaterial products. The Company sells its products to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com. Safe Harbor Statement This news release may contain certain "forward-looking statements" relating to the business of China Biologic Products Holdings, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein, are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "intend," "believe," "expect," "are expected to," "will," or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including, without limitation, quality of purchased source plasma, potential delay or failure to complete construction of new collection facilities, potential inability to pass government inspection and certification process for existing and new facilities, potential inability to achieve the designed collection capacities at the new collection facilities, potential inability to achieve the expected operating and financial performance, potential inability to find alternative sources of plasma, potential inability to increase production at permitted sites, potential inability to mitigate the financial consequences of a temporarily reduced raw plasma supply through cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements. Contact: China Biologic Products Holdings, Inc.Mr. Ming YinSenior Vice President Email: [emailprotected] The Foote Group Mr. Philip LisioPhone: +86-135-0116-6560Email: [emailprotected] SOURCE China Biologic Products Holdings, Inc. Related Links http://www.chinabiologic.com

China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction

LOS ANGELES--(BUSINESS WIRE)--KB Home (NYSE: KBH) has been named to Forbes 2021 list of Americas Best Midsize Employers, the only national homebuilder to receive this distinction. This recognition is presented by Forbes and Statista, a leading provider of market and consumer data, and can be viewed on Forbes website. Were honored to be named by Forbes as one of Americas Best Midsize Employers in recognition of our comprehensive approach to cultivating a workplace that is focused on the growth and development of our employees, said Jeffrey Mezger, KB Homes Chairman, President and Chief Executive Officer. We are proud to be the only national homebuilder to make this distinguished list. This distinction is testament to our supportive and inclusive culture that has been a core part of our business for over 60 years. At KB Home, we appreciate and value our employees dedication and passion for advancing our vision to be the most customer-obsessed homebuilder in the world. Forbes list of Americas Best Employers has been published in partnership with Statista, a market research company, since 2015. The list identifies companies liked best by employees based on an anonymous survey of 50,000 Americans. Respondents are asked detailed questions about the working conditions of their company and how likely they are to recommend their employer to others on a scale of zero to ten. The final list ranks a total of 1,000 companies: 500 large (over 5,000 employees) and 500 midsize (1,000 to 5,000 employees). For more information on KB Home, call 888-KB-HOMES or visit kbhome.com. About KB Home KB Home is one of the largest and most recognized homebuilders in the United States and has been building quality homes for over 60 years. Today, KB Home operates in 45 markets across eight states, serving a wide array of buyer groups. What sets us apart is how we give our customers the ability to personalize their homes from homesites and floor plans to cabinets and countertops, at a price that fits their budget. We are the first builder to make every home we build ENERGY STAR certified. In fact, we go beyond the EPA requirements by ensuring every ENERGY STAR certified KB home has been tested and verified by a third-party inspector to meet the EPAs strict certification standards, which help to lower the cost of ownership and to make our new homes healthier and more comfortable than new ones without certification. We also work with our customers every step of the way, building strong personal relationships so they have a real partner in the homebuying process, and the experience is as simple and easy as possible. Learn more about how we build homes built on relationships by visiting kbhome.com.

Forbes Names KB Home One of Americas Best Employers Homebuilders dedicated focus on leading employment practices earns company a place on 2021 list.

COLUMBIA, Md.--(BUSINESS WIRE)--Corporate Office Properties Trust (NYSE: OFC) (COPT or the Company) executed a long-term lease with a Fortune 500 company for a 265,000 square foot, build-to-suit development in Northern Virginia. The facility is scheduled for shell completion in the second quarter of 2022. About COPT COPT is a REIT that owns, manages, leases, develops and selectively acquires office and data center properties. The majority of its portfolio is in locations that support the United States Government and its contractors, most of whom are engaged in national security, defense and information technology (IT) related activities servicing what it believes are growing, durable, priority missions (Defense/IT Locations). The Company also owns a portfolio of office properties located in select urban/urban-like submarkets in the Greater Washington, DC/Baltimore region with durable Class-A office fundamentals and characteristics (Regional Office Properties). As of March 31, 2021, the Company derived 88% of its core portfolio annualized rental revenue from Defense/IT Locations and 12% from its Regional Office Properties. As of the same date and including 17 properties owned through unconsolidated joint ventures, COPTs core portfolio of 180 office and data center shell properties encompassed 20.8 million square feet and was 94.9% leased; the Company also owned one wholesale data center with a critical load of 19.25 megawatts that was 86.7% leased. Forward-Looking Information This press release may contain forward-looking statements, as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are based on the Companys current expectations, estimates and projections about future events and financial trends affecting the Company. Forward-looking statements can be identified by the use of words such as may, will, should, could, believe, anticipate, expect, estimate, plan or other comparable terminology. Forward-looking statements are inherently subject to risks and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate. Although the Company believes that the expectations, estimates and projections reflected in such forward-looking statements are based on reasonable assumptions at the time made, the Company can give no assurance that these expectations, estimates and projections will be achieved. Future events and actual results may differ materially from those discussed in the forward-looking statements and the Company undertakes no obligation to update or supplement any forward-looking statements. The areas of risk that may affect these expectations, estimates and projections include, but are not limited to, those risks described in Item 1A of the Companys Annual Report on Form 10-K for the year ended December 31, 2020. Source: Corporate Office Properties Trust

COPT Executes a 265,000 SF Build-To-Suit Lease in Northern Virginia

SAN FRANCISCO, March 19, 2021 /PRNewswire/ --Shorenstein Properties, LLC ("Shorenstein"), an owner and operator of high-quality office, residential and mixed-use properties across the U.S., today announced the sale of 2 & 3 MiamiCentral to funds managed by Blackstone Real Estate ("Blackstone") for approximately $230 million. Located in Downtown Miami, this approximately 330,000 square-foot property is directly adjacent to the MiamiCentral train station and serves as the ideal location for employees commuting across South Florida through the public transportation system or commuting via automobile. 2 & 3 MiamiCentral has been recognized by industry-leading organizations for the building's environmental stewardship, with certifications from The U.S. Green Building Council's LEED and ENERGY STAR. In addition to Blackstone's Technology & Innovations group, which occupies approximately 12% of the space at 2 MiamiCentral to accommodate the 200 employees it is hiring to join the technology team, the property has national, institutional tenants including Carlton Fields, Ernst & Young, New Fortress Energy and ViacomCBS. The MiamiCentral station project also houses retail and residential space, including a Publix supermarket on the ground floor of 3 MiamiCentral. In total, the buildings are 98% occupied with remaining lease terms of more than eight years on average. "We are pleased to have completed the sale of 2 & 3 MiamiCentral," said Claude Esposito, Vice President, Investments Group at Shorenstein. "This deal is a great example of executing on our thesis of investing in high quality properties in growing markets and adding significant value through leasing and capital improvements. We are proud to have positioned the property for future success and know that the tenants of 2 & 3 MiamiCentral are in good hands with Blackstone Real Estate." David Levine, Senior Managing Director in Blackstone Real Estate, added, "We are high conviction, thematic investors focused on investing in growing markets with strong demographic tailwinds and talent pipelines, such as Miami. 2 & 3 MiamiCentral are extremely high-quality assets in a prime location with access to mass transit, and we are pleased to acquire them on behalf of our investors." Shorenstein's presence in South Florida also includes The Main Las Olas inDowntown Fort Lauderdale. This brand new, just delivered 25-story mixed-use development with a 385,000-square-foot Class A office building is currently leasing to prospective tenants. The Main Las Olas' adjacent residential tower, Novo Las Olas, houses Fort Lauderdale'sfirst Publix GreenWise on its ground floor. The Main Las Olas is just four blocks from Brightline's Fort Lauderdale Station, and has world class amenities including covered and uncovered outdoor terraces with ocean views, club rooms, lounges, flex multipurpose spaces and a state-of-the-art fitness center, with plans to include a high-end restaurant and casual eateries on the ground floor of the office building. Designed with health and wellness as a priority for tenants, the building also offers ionized air filtration systems, touchless front entry in common areas and building access by FOB or cell phone. South Florida continues to benefit from the ongoing surge in business activity and migration, with Fort Lauderdale representing one of the most attractive destinations in the region. For more information on The Main Las Olas, please visit www.themainlasolas.com. About Shorenstein Properties LLCFounded in 1924, Shorenstein Properties LLC is a privately-owned, real estate firm that owns and operates high-quality office, residential and mixed-use properties across the U.S., with offices in San Francisco and New York. Since 1992, Shorenstein has sponsored twelve closed-end investment funds with total equity commitments of $8.8 billion, of which Shorenstein committed $723.5 million. The firm uses its integrated investment and operating capabilities to take advantage of opportunities that, at the particular time in the investment cycle, offer the most attractive returns. Investments have included ground-up developments, asset repositioning and stabilized assets; investment structures have included asset acquisitions, mezzanine loans, preferred equity investments and structured joint ventures. These funds have invested in properties totaling 67 million square feet in transactions with a gross investment value in excess of $16 billion. More information is available at www.shorenstein.com. Contacts ShorensteinJon Keehner / Jed Repko / Julie Hamilton / Jack KelleherJoele Frank, Wilkinson Brimmer Katcher212.355.4449 / 415.869.3950 SOURCE Shorenstein Properties LLC

Shorenstein Properties Sells 2 & 3 MiamiCentral to Funds Managed by Blackstone Real Estate

DENVER, July 16, 2020 /PRNewswire/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce that, further to its press release of July 14, 2020, its prospective acquisition target NeuroPharm Inc. ("NeuroPharm"), a developer of natural health, psychedelic based treatments for PTSD and other serious mental health disorders in veterans and frontline workers, has entered into a collaborative relationship with Leiden University Medical Center of The Netherlands ("LUMC") for the initiation of clinical trials. The project, "NeuroPharm Veteran PTSD Research Project (NVPRP)," is preparing an IRB-ready protocol to be used for a LUMC based clinical trial for the specific treatment of PTSD in veterans. ARQ National Psychotrauma Centre will also play a significant role in the execution of this trial. LUMC is the hospital affiliated with Leiden University located in Leiden, Netherlands. Leiden University, founded in 1575, is one of Europe's leading international research universities. NeuroPharm selected LUMC due to its established position as a world-recognized leader in the research and study of psilocybin (a psychedelic chemical naturally found in certain varietals of mushrooms). In previous work, Leiden University researchers have found that micro doses of psilocybin can stimulate brain function without harming reasoning abilities. The NVPRP will couple NeuroPharm's scientific, academic, and clinical trial expertise with LUMC's leading edge psilocybin research and development. Leading the Leiden work on NeuroPharm's behalf is Professor H.G.J.M. (Eric) Vermetten MD, Ph.D.Colonel, an internationally recognized leader in the treatment of PTSD and other mental disorders. Dr. Vermetten, an active Colonel of the Dutch military, serves as professorMedical-Biological and Psychiatric Aspects of Psychotrauma, LUMC/University of Leiden.Dr. Vermettenis psychiatrist at the MGGZ in Utrecht (Military Mental Health care) and has served as a researcher in conjunction with Stanford University, Yale University and Emory University. The protocols being developed with Dr. Vermetten are to be employed for veteran-based clinical trials for the treatment of PTSD with psilocybin assisted psychotherapy.The inceptive LUMC trial will serve as the basis for a series of follow-on trials conducted in Canada and the United States. "Despite several evidence-based treatment options for Veterans suffering with PTSD, we know that many still do not respond. It is important to continue the search for safe and effective treatments to help those that are suffering after sacrificing so much for nations," Dr Vermetten stated. "Psilocybin assisted psychotherapy has the potential to be a game changer in the treatment of PTSD in Veterans and it seems natural that a Dutch/Canadian collaboration will lead the way," Dr. Rekesh Jetly added, COO of NeuroPharm. The Company's prospective acquisition of 100% of the issued and outstanding shares of NeuroPharm (the "Acquisition") is subject to a number of conditions, including, but not limited to, completion of satisfactory due diligence and regulatory approval. There can be no assurance that the Acquisition will be completed as proposed, or at all. Mydecine Innovations Group Inc. Mydecine Innovations Group is a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions. Mydecine's experienced cross functional teamdynamic hasthe capabilities to oversee all areas of drug development including synthesis, drug delivery system development, clinical trial execution, through to product commercialization and marketing. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is at the forefront of the efficient development of psychedelic derived medicines and therapeutic solutions. Our trailblazing portfolio of companies is focused on providing innovative and effective treatment options that can help millions of people live healthier lives. About NeuroPharm Inc. NeuroPharm Inc. is a Canadian-based healthcare company developing a unique set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations. It is committed to bringing to market adaptive plant-based therapies for use as an adjunct to clinical therapy to treat traumatic disorders specifically observed in veterans and first responders. NeuroPharm was founded by a dedicated group of former military personnel motivated to seek alternative treatments addressing these traumatic disorders experienced by many veterans following active service. The management team is proud to include contributions and advisory from esteemed scientific, academic, clinical and product development specialists. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. Forward-Looking Information Cautionary StatementThis press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements". Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information contained herein may include, but is not limited to: the successful completion of the Acquisition; NeuroPharm's development of certain technologies and products; NeuroPharm's initiation of clinical trials and timing thereof; NeuroPharm's successful completion of clinical trials; NeuroPharm's filing of certain patent applications; and the Company's ability to fund NeuroPharm's capital requirements. By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this notice. An investment in securities of the Company is speculative and subject to several risks including, without limitation, the risks discussed under the heading "Risks and Uncertainties" in the Company's management discussion and analysis for the year endedDecember 31, 2019and filed on the Company's SEDAR profile. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information and forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. This news release does not constitute an offer of securities for sale in the United States. The Company's securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold inthe United Statesor to a U.S. Person unless so registered, or an exemption from registration is relied upon. On Behalf of the Board of DirectorsJoshua BartchChief Executive Officer[emailprotected]+1-250-488-6728 SOURCE Mydecine Innovations Group Inc.

Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading European Research Institute

MAUMEE, Ohio, Aug. 5, 2020 /PRNewswire/ --Dana Incorporated (NYSE: DAN) announced today it will present at the J.P. Morgan Auto Conference on August 12, 2020. Beginning at 12:20 p.m. EDT, Dana's Chairman and Chief Executive Officer James Kamsickas and Executive Vice President and Chief Financial Officer Jonathan Collins will provide a brief overview of the company and answer questions for approximately 30 minutes. Information on accessing the webcast will be posted to Dana's Investor website, www.dana.com/investors, prior to the event. About Dana Incorporated Dana is a world leader in providing power-conveyance and energy-management solutions that are engineered to improve the efficiency, performance, and sustainability of light vehicles, commercial vehicles, and off-highway equipment. Enabling the propulsion of conventional, hybrid, and electric-powered vehicles, Dana equips its customers with critical drive and motion systems; electrodynamic technologies; and thermal, sealing, and digital solutions. Founded in 1904, Dana employs more than 36,000 people who are committed to delivering long-term value to their customers, which include nearly every vehicle manufacturer in the world. Based in Maumee, Ohio, USA, and with locations in 34 countries across six continents, the company reported sales of $8.6 billion in 2019. Having established a high-performance culture that focuses on its people, the company has earned recognition around the world as a top employer. Learn more at dana.com. SOURCE Dana Incorporated Related Links http://www.dana.com

Dana Incorporated to Participate in J.P. Morgan Auto Conference

SUZHOU, China, April 15, 2020 /PRNewswire/ -- New treatments designed to prevent cancer from developing, based on changing the microenvironment in which cancer cells evolve, could be both feasible and effective. This is the outcome of research published by Open Biology today, exploring the theoretical aspects of cancer evolution, potentially paving the way to better targeted anti-cancer prevention and treatment strategies. The research, by Dr Xiaowei Jiang, a lecturer in bioinformatics at Xi'an Jiaotong-Liverpool University (XJTLU) in China, and Professor Ian Tomlinson, Director, Cancer Research UK Edinburgh Centre, relates to diverse changing tumour microenvironments and their impact on cancer cell population growth in the body. Dr Jiang says that cancers could be managed by killing cancer cells through imposing a changing microenvironment. "Cancer development has long been viewed as a Darwinian evolutionary process, in which a changing tumour microenvironment (TME) is likely to play a critical role. Very few cancer modelling studies have considered how broadly the TME changing dynamics affect cancer evolution," Dr Jiang says. "In our research we establish a mathematic model of cancer evolution with changing microenvironments in 3D, which generates far more complex patterns of cancer adaptation and predicts tumour morphologies resembling those observed clinically." Dr Jiang says that the challenge that changing TMEs present to cancer evolution are also indicative of why cancer is neither inevitable nor as common as expected. "It's an unsolved puzzle-- trying to understand why so few cancers occur compared with the theoretical number that could occur," says Dr Jiang. "Although cancer is viewed as a common disease, our current knowledge of how cancers grow suggests that cancer is actually far less frequent than we expect; the mutation rates and number of normal cells suggest that many cancers could occur in each human. " "There are several potential reasons for the 'cancer deficiency', including anti-cancer immune responses and inherent mechanisms of tissue homoeostasis (or "buffering")." "We hypothesised that a further contributory factor restraining carcinogenesis is that the TME is not fixed, and that this could impair the ability of neoplastic cells to retain a high enough Darwinian fitness to become a cancer." "Compared with static TMEs which generate neutral dynamics, changing TMEs lead to complex adaptations with spatio-temporal heterogeneity involving variable fitness effects of driver mutations, sub-clonal mixing, sub-clonal competition and phylogeny patterns." "In many cases, cancer cell populations fail to grow or undergo spontaneous regression, and even extinction." "Imagine a sunflower growing in a greenhouse with exposure to sunlight in the same position each day. The chances are its growth will be more regular and uniform than a similar plant growing in the back of a moving vehicle, full of other items and travelling at speed, where the likelihood of its blossoming is far less certain," Dr Jiang says. Reference: Jiang X, Tomlinson IPM. 2020 Why is cancer not more common? A changing microenvironment may help to explain why, and suggests strategies for anticancer therapy. Open Biol. 10: 190297. To be published: http://dx.doi.org/10.1098/rsob.190297 SOURCE Xi'an Jiaotong-Liverpool University Related Links www.xjtlu.edu.cn

New cancer treatments could follow research into cancer evolution

ALBANY, New York, July 16, 2020 /PRNewswire/ -- Impressive demand for extensive operational abilities across the healthcare sector may serve as a prominent growth generator for the operating room equipment marketacross 2018-2026. Hybrid operating rooms may serve as a growth accelerator for the operating room equipment market during the forecast period. A hybrid operating room consists of advanced equipment and offers enhanced convenience to healthcare professionals for performing complex surgeries. The increasing investment in the healthcare infrastructure is also an important component for the growth of the operating room equipment market. The global operating room equipment market is expected to expand at a CAGR of 6.4% across the forecast period of 2018-2026 according to the scrutinized diagnosis by the analysts of Transparency Market Research (TMR). The global operating room equipment market was valued at US$ 29,912.3 mn in 2017 and is construed to reach US$ 51,858.7 mn by 2026. Download a PDF Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1674 The addition of advanced technologies like the Internet of Things (IoT) and Artificial Intelligence (AI) to operating room equipment is attracting considerable attention from the stakeholders in the healthcare sector. The growing need for advanced healthcare infrastructure in remote areas may extend the growth possibilities of the operating room equipment market. Operating Room Equipment Market: Pivotal Findings The patient monitoring segment is extrapolated to expand at a CAGR of 8.1% across the forecast period Hybrid operating rooms my serve as prominent growth accelerators for the operating room equipment market North America held an eminent position in 2017 in terms of regional growth and expects to continue the same throughout the forecast period Asia Pacific may bag the title of the fastest-growing region in terms of growth across 2018-2026 Explore 216 pages of in-depth research, incisive insights, and detailed country-level projections. Analyze and discover the latest developments in the Operating Room Equipment Market (Product Type - Anesthesia and Respiratory Devices (Anesthesia Systems, Patient Warmers, Ventilators), Patient Monitoring (Surgical Imaging Displays, Movable Imaging Displays, Vital Signs Monitoring Devices), Surgical Equipment (Electrical Surgical Units, Handheld Surgical Instruments, Operating Tables, Operating Room Lights, Surgical Booms), Others (Microscopes, Endoscopes, Operating Room Integration Systems); End user - Hospitals, Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018 2026 at https://www.transparencymarketresearch.com/report-toc/1674 Operating Room Equipment Market: Promising Growth Avenues Technological advancements are proving to be an important component for the growth of the operating room equipment market. The growing need for high-resolution imaging across the healthcare sector may bring great growth prospects for the operating room equipment market The swift rise in geriatric population and the growing incidence of chronic diseases may bring tremendous growth opportunities for the operating room equipment market Growing awareness about the latest healthcare technologies across the globe may bring immense growth for the operating room equipment market Ambulatory surgical centers (ASCs) are also bringing considerable demand for operating tables, operating room lights, etc Purchase the Operating Room Equipment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1674&ltype=S How are Government Initiatives Strengthening Operating Room Equipment Market? Government support is at an all-time high for improving the healthcare infrastructure across their respective countries. The governments of various countries are trying to spin a strong web of healthcare facilities across remote and rural regions. Countries like India in Asia Pacific are assuring good growth for the operating room equipment market through healthcare infrastructure boosting initiatives like National Rural Health Mission and National Rural Urban Mission. Robust healthcare policies provided by the government to its citizens are also playing a larger role in increasing the reach of healthcare to the last person in the country. This aspect may serve as a great growth multiplier for the operating room equipment market. Inquire for a Sample Copy of Report -https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1674 The global operating room equipment market has been segmented as follows: By Product Type Anesthesia and Respiratory Devices Patient Monitoring Surgical Equipment Others By End-user Hospitals Ambulatory Surgical Centers Others By Region North America Europe Asia Pacific Latin America Middle East & Africa Explore Transparency Market Research's award-winning coverage of the global Healthcare industry: Hybrid Operating Room Market: Hybrid Operating Room Market's opportunity is anticipated to reach US$661.8 mn by 2017. It is further expected to proliferate at a CAGR of 4.60% between 2017 and 2022, increasing to US$828.1 bn by the end of 2022. The global market for hybrid operating rooms is gaining tremendously from the significant rise in technological advancements, especially in emerging economies. Respiratory Devices Market: Respiratory Devices Market is anticipated to growth at a moderate CAGR of 6.5% between 2018 and 2026 (forecast period). In the year 2017, the respiratory devices market stood at a value of US $ 17 billion. If the market scales at predicted CAGR, then the market size is projected to grow equivalent to US$ 31.0 Bn by the end of 2026. Patient Monitoring and Ultrasound Devices Display Market: The global market for patient monitoring and ultrasound devices display is anticipated to expand at a revenue CAGR of 5.1% during the forecast period from 2017 2025. The global patient monitoring and ultrasound devices display market is expected to reach US$ 4,605.4 Mn by 2025. Rise in demand for advanced diagnostic technology with high contrast and best resolution display is expected to boost the market. Gain access to Market Ngage, an AI-powered, real-time business intelligence that goes beyond the archaic research solutions to solve the complex strategy challenges that organizations face today. With over 15,000+ global and country-wise reports across 50,000+ application areas, Market Ngage is your tool for research on-the-go. From tracking new investment avenues to keeping a track of your competitor's moves, Market Ngage provides you with all the essential information to up your strategic game. Power your business with Market Ngage's actionable insights and remove the guesswork in making colossal decisions. About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key tohelp enterprises reach right decision. ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: [emailprotected]Website: https://www.transparencymarketresearch.com/ SOURCE Transparency Market Research

Penetration of Robust Healthcare Facilities in Remote Areas to Assist Greatly in Growth of Operating Room Equipment Market, North America to Hold Prominent Position, Opines TMR

NEW YORK, Oct. 8, 2020 /PRNewswire/ -- Tanya Zuckerbrot, MS, RD, internationally respected dietetic expert, founder and CEO of theF-Factor diet, filed a lawsuit today in New York State Court against influencer Emily Gellis for publishing over 4,500 false, defamatory and/or harassing statements for over 75 consecutive days since July of 2020, including as recently as today. Zuckerbrot is represented by Dan Webb, former United States Attorney in Chicago, and Lanny J. Davis, former Special Counsel to President Bill Clinton. The complaint includes a detailed history of Gellis' unrelenting posts, and the lack of regard for published product labels and certified F-Factor company information. Specific examples include: The continued attacks against Zuckerbrot personally, including the false assertion that Zuckerbrot threatened to kill Gellis' family, poisoned people daily, engaged in criminal wrongdoing, and sent people to physically harm Gellis. The threatening posts by Gellis that caused Zuckerbrot to fear for her life and the safety of her family and employees and the exposure of Zuckerbrot's home address and that of her children. Gellis telling her followers that the F-Factor diet caused miscarriages, without any factual basis whatsoever for such a heinous accusation and in spite of the fact that an individual who told Gellis she suffered a miscarriage admitted, to the New York Times, that it was a lie. The false statements Gellis sent to her followers that F-Factor products caused damage to intestinal lining, heart attacks, or death in some cases. The recapitulation of Gellis' narrative that F-Factor products contain harmful levels of arsenic. The complaint alleges that Gellis' smear campaign resulted in extensive financial and reputational harm to Zuckerbrot and F-Factor. According to the complaint, Gellis' false and defamatory statements misled consumers about the safety of the F-Factor diet and F-Factor products, leading to a major reduction in F-Factor's monthly revenue and overall valuation, the withdrawal of a planned lucrative capital investment in the company, and significant damage to the professional reputations of Zuckerbrot and F-Factor. On top of these considerable financial and reputational injuries, Gellis' constant and malicious harassment of Zuckerbrot and her company caused severe emotional distress to Zuckerbrot. To redress these substantial losses and prevent further misconduct, Zuckerbrot and F-Factor seek compensatory and punitive damages from Gellis. The complaint also includes potential motives for Gellis' continued attacks, including massive follower growth and corresponding financial gain that often accompanies it. Damage caused by the defendant on F-Factor goes beyond financial ramifications, with her accusations threatening jobs, families, immunocompromised and at-risk individuals in need of structured nutrition, and the marginalized communities that receive aid from F-Factor philanthropies. The lawsuit further discusses the failure of Facebook and Instagram to enforce their "Community Standards" which ultimately facilitated Gellis' misconduct. Despite extensive efforts by Zuckerbrot and F-Factor, no action was taken to remedy or cease the continued abuse on behalf of these platforms. Though not named defendants, the suit calls out the lack of accountability exhibited by both. "The Defendant Gellis may think she is immune from accountability for false, defamatory and/or harassing statements she made to substantially harm Tanya Zuckerbrot and F-Factor because she made the statements on social media platforms," said Dan Webb and Lanny J. Davis, co-counsel in the case against Gellis. "But she is wrong, and we believe a jury of her peers in New York City will ultimately agree that her conduct is unlawful and maliciously reprehensible." F-Factor employs 80% women, and provided a higher median salary for its employees comparatively within the industry, in addition to its frequent community outreach that saw 250,000 bars donated to frontline workers during the pandemic, and massive donations to foodbanks across the US, amongst other programs. For more information please visit F-Factor's Correcting the Record Website: https://www.ffactor.com/facts/ For more information on the complaint, please visit: https://www.ffactor.com/wp-content/uploads/2020/10/FFcomplaint.pdf About Tanya Zuckerbrot Tanya Zuckerbrot, MS, RD, is an internationally-known dietitian, a two-time bestselling author, and the creator and CEO of the renowned F-Factor Dieta liberating and sustainable approach to weight loss and optimal health based on scientifically proven fiber-rich nutrition. Zuckerbrot has worked in private practice for more than 20 years and has advised thousands of clients including celebrities, business and government leaders, and media personalities to improve their health and manage their weight through nutrition. In addition to working with private clients, Zuckerbrot is a lecturer, consultant, spokesperson, and national media personality. In 2017, Zuckerbrot transitioned from clinician to CEO and oversaw operations of F-Factor from the ground up, releasing several successful products including F-Factor 20/20 Fiber/Protein Powders and Bars certified and produced with Zuckerbrot's philosophy and approach. With Zuckerbrot's leadership, F-Factor employs more than 80% women and advocates and provides higher median salaries for F-Factor Registered Dietitians than the national average for the profession. As founder and CEO, Zuckerbrot instilled a strong ethos for F-Factor to help those in need. For example, during the COVID-19 pandemic, F-Factor donated over 250,000 F-Factor Bars to over 200 hospitals, food banks and shelters across the country to support essential workers and those facing food insecurity. Zuckerbrot's philanthropy extends outside the office as well, she is a Board Member of several philanthropic organizations. Zuckerbrot holds a master's degree in Nutrition and Food Studies from New York University; is an accredited member of the American Dietetic Association, the Greater New York Dietetic Association, and the American Association for Diabetes Educators; and is a member of the National Association of Professional Women. Zuckerbrot holds a Commission of Dietetic Registration (CDR) Certificate of Training in Adult Weight Management as well as a CDR Certificate of Training in Childhood and Adolescent Weight Management. About F-Factor Fad diets come and go, but after more than two decades of success stories and ongoing praise from the media, The F-Factor Diet has stood the test of time. Now hailed as the go-to lifestyle program for anyone who wants to improve their health and lose weight for good, F-Factor's scientifically proven approach allows you to see results without hunger, deprivation, or denial. Change your life without disrupting your lifestyle: dine out, drink alcohol, eat carbs, and workout less from Day 1. The F-Factor Program has been endorsed by numerous physicians and dieticians, including Dr. Jerome Zacks, Assistant Clinical Professor at the Mount Sinai Medical Center: "The F-Factor Diet is packed with critical facts that form the foundation for a knowledge-based approach to lifestyle nutritional success. Tanya's scholarly approach is a gift that gives forever. Her contribution to preventative health care is immeasurable." To learn more about the F-Factor Program, the bestselling F-Factor Diet Book, and F-Factor products visit our website at https://www.ffactor.com To ask questions of attorneys Dan Webb and Lanny Davis Please email/call: [emailprotected] 202-460-1451 or 202-480-3309 Press Availability: 2 PM ET/1 PM CT SOURCE F-Factor Related Links https://www.ffactor.com

Instagram user Emily Gellis sued by CEO and Founder Tanya Zuckerbrot and F-Factor for over 4,500 recklessly false, defamatory and/or harassing messages Facebook and Instagram cited as enabling Gellis' abusive misconduct and for failing and refusing to enforce their own adopted standards